carnitine has been researched along with Schizophrenia in 10 studies
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our pilot study suggests that linoelaidyl carnitine levels at baseline may have a predictive role for the improvement of positive symptoms after OLA monotherapy in the patients with schizophrenia." | 8.12 | Plasma linoelaidyl carnitine levels positively correlated with symptom improvement in olanzapine-treated first-episode drug-naïve schizophrenia. ( Li, X; Su, X; Wang, K; Wang, X; Wu, F; Xiu, M, 2022) |
| "We sought to compare serum carnitine levels and clinical correlates between stable outpatients and acutely hospitalised individuals with diagnoses of bipolar disorder and schizophrenia." | 7.83 | Comparison of serum carnitine levels and clinical correlates between outpatients and acutely hospitalised individuals with bipolar disorder and schizophrenia: A cross-sectional study. ( Abramson, RK; Breen, RJ; Cuturic, M; Edwards, AC; Levy, EE, 2016) |
| "Subjects with schizophrenia have high risks of metabolic abnormalities and bioenergetic dysfunction." | 5.51 | Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study. ( Brietzke, E; Cao, B; Huang, N; Mansur, RB; McIntyre, RS; Musial, N; Pan, Z; Subramanieapillai, M; Wang, D; Wang, J; Zeng, J, 2019) |
| "Our pilot study suggests that linoelaidyl carnitine levels at baseline may have a predictive role for the improvement of positive symptoms after OLA monotherapy in the patients with schizophrenia." | 4.12 | Plasma linoelaidyl carnitine levels positively correlated with symptom improvement in olanzapine-treated first-episode drug-naïve schizophrenia. ( Li, X; Su, X; Wang, K; Wang, X; Wu, F; Xiu, M, 2022) |
| "We sought to compare serum carnitine levels and clinical correlates between stable outpatients and acutely hospitalised individuals with diagnoses of bipolar disorder and schizophrenia." | 3.83 | Comparison of serum carnitine levels and clinical correlates between outpatients and acutely hospitalised individuals with bipolar disorder and schizophrenia: A cross-sectional study. ( Abramson, RK; Breen, RJ; Cuturic, M; Edwards, AC; Levy, EE, 2016) |
| "Subjects with schizophrenia have high risks of metabolic abnormalities and bioenergetic dysfunction." | 1.51 | Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study. ( Brietzke, E; Cao, B; Huang, N; Mansur, RB; McIntyre, RS; Musial, N; Pan, Z; Subramanieapillai, M; Wang, D; Wang, J; Zeng, J, 2019) |
| "As carnitine deficiency is a potentially treatable condition further studies are warranted." | 1.37 | Clinical correlates of low serum carnitine levels in hospitalized psychiatric patients. ( Abramson, RK; Cuturic, M; Hall, AV; Hardin, JW; Moran, RR, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, X | 1 |
| Xiu, M | 1 |
| Wang, K | 1 |
| Su, X | 1 |
| Li, X | 1 |
| Wu, F | 1 |
| Cao, B | 3 |
| Chen, Y | 1 |
| McIntyre, RS | 3 |
| Yan, L | 1 |
| Jin, M | 1 |
| Brietzke, E | 2 |
| Wang, D | 2 |
| Rosenblat, JD | 1 |
| Ragguett, RM | 1 |
| Zhang, C | 1 |
| Sun, X | 1 |
| Rong, C | 1 |
| Wang, J | 2 |
| Wang, W | 1 |
| Bai, M | 1 |
| Jiang, T | 1 |
| Li, C | 1 |
| Li, P | 1 |
| Zhou, H | 1 |
| Wang, Z | 1 |
| Li, L | 1 |
| Jiang, H | 1 |
| Costa, AC | 1 |
| Joaquim, HPG | 1 |
| Talib, LL | 1 |
| Serpa, MH | 1 |
| Zanetti, MV | 1 |
| Gattaz, WF | 1 |
| Pan, Z | 1 |
| Musial, N | 1 |
| Mansur, RB | 1 |
| Subramanieapillai, M | 1 |
| Zeng, J | 1 |
| Huang, N | 1 |
| Moos, WH | 1 |
| Maneta, E | 1 |
| Pinkert, CA | 1 |
| Irwin, MH | 1 |
| Hoffman, ME | 1 |
| Faller, DV | 1 |
| Steliou, K | 1 |
| Cuturic, M | 2 |
| Abramson, RK | 2 |
| Breen, RJ | 1 |
| Edwards, AC | 1 |
| Levy, EE | 1 |
| Moran, RR | 1 |
| Hardin, JW | 1 |
| Hall, AV | 1 |
| Sonik, P | 1 |
| Hilty, DM | 1 |
| Rossaro, L | 1 |
| Bourgeois, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy of L-Carnitine in the Management of Acute Clozapine Intoxication[NCT05632094] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-06-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for carnitine and Schizophrenia
| Article | Year |
|---|---|
Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia.
Topics: Animals; Autism Spectrum Disorder; Carnitine; Epigenomics; Humans; Mitochondria; Neuroprotective Age | 2016 |
1 trial available for carnitine and Schizophrenia
| Article | Year |
|---|---|
Serum metabolic profiling using small molecular water-soluble metabolites in individuals with schizophrenia: A longitudinal study using a pre-post-treatment design.
Topics: Adolescent; Adult; Amino Acids; Antipsychotic Agents; Biomarkers; Carnitine; Female; Humans; Longitu | 2019 |
8 other studies available for carnitine and Schizophrenia
| Article | Year |
|---|---|
Plasma linoelaidyl carnitine levels positively correlated with symptom improvement in olanzapine-treated first-episode drug-naïve schizophrenia.
Topics: Carnitine; Humans; Metabolomics; Olanzapine; Pilot Projects; Schizophrenia | 2022 |
Acyl-Carnitine plasma levels and their association with metabolic syndrome in individuals with schizophrenia.
Topics: Adult; Biomarkers; Carnitine; Case-Control Studies; Female; Humans; Male; Metabolic Syndrome; Plasma | 2020 |
Clozapine-induced reduction of l-carnitine reabsorption via inhibition/down-regulation of renal carnitine/organic cation transporter 2 contributes to liver lipid metabolic disorder in mice.
Topics: Animals; Antipsychotic Agents; Carnitine; Cell Line; Chemical and Drug Induced Liver Injury; Clozapi | 2019 |
Plasma metabolites in first episode psychoses.
Topics: Adolescent; Adult; Biomarkers; Bipolar Disorder; Carnitine; Female; Humans; Lysophosphatidylcholines | 2019 |
Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study.
Topics: Adult; Biomarkers; Carnitine; Case-Control Studies; China; Chromatography, Liquid; Energy Metabolism | 2019 |
Comparison of serum carnitine levels and clinical correlates between outpatients and acutely hospitalised individuals with bipolar disorder and schizophrenia: A cross-sectional study.
Topics: Adult; Bipolar Disorder; Carnitine; Cross-Sectional Studies; Female; Hospitalization; Humans; Inpati | 2016 |
Clinical correlates of low serum carnitine levels in hospitalized psychiatric patients.
Topics: Adult; Aged; Antimanic Agents; Carnitine; Female; Humans; Inpatients; Male; Mental Disorders; Middle | 2011 |
Carnitine supplementation for valproate-related hyperammonemia to maintain therapeutic valproate level.
Topics: Adult; Anticonvulsants; Antisocial Personality Disorder; Carnitine; Humans; Hyperammonemia; Male; Sc | 2011 |